Insights / Activity
Posts carrying the Venture Investment tag.
31 Mar 2026 · 3 min read
Eli Lilly’s third Insilico deal in three years: $115M upfront, up to $2.75B in milestones, plus royalties. The progression from software licensing in 2023 to a $2.75B commitment in 2026 tells the real story. The signal for the rest of the AI drug discovery space is harder to read — deals like this concentrate pharma attention on proven platforms.
26 Mar 2026 · 3 min read
A company you’ve most likely never heard of just raised $787M for AI-driven biologics. The headline number is striking. Sanofi’s trajectory — partner to repeat customer to investor in under twelve months — tells you more about the platform than any press release. The Delaware-incorporated, Beijing-operating structure is the emerging architecture for Chinese AI biotech going global.
29 Jan 2026 · 3 min read
Hologen, Eric Schmidt’s stealth biotech-AI venture, is raising $150M at an $850M pre-money on a promise of 100% returns in 12 months. The pitch is closer to financial underwriting than AI product development. Here’s what would convince me it’s more than narrative.
20 Nov 2025 · 1 min read
Jeff Bezos just bet $106M on Profluent, a company using frontier AI models to design proteins that don't exist in nature — and I break down exactly what makes these models 'frontier' and why it matters for programmable biology.
8 Oct 2025 · 3 min read
I joined an inspiring panel this morning at BioTechX with investors from Flagship Pioneering, Hikma Pharmaceuticals, MTIP, Lauxera Capital Partners, and Archimed to discuss where we stand on the journey of cracking biology and health with AI. From agentic AI and defensible moats to the tech-bio platform vs. pipeline dilemma and whether we're in an AI bubble, the conversation covered the full frontier.
18 Jul 2025 · 1 min read
It's great to see more unicorns in health tech AI — OpenEvidence is now valued at more than $3.5B after a $210M Series B backed by Sequoia, Kleiner Perkins, GV, and Coatue. GenAI is clearly starting to move beyond the pilot phase into daily clinical practice, and the AI hype cycle in health tech venture investment shows no signs of ending just yet.
10 Jun 2025 · 1 min read
I look at Omada Health's IPO following Hinge Health's successful public debut, noting that the valuation reflects a new market reality prioritizing a clear path to profitability over hyper-growth. I'm encouraged by the early performance but remain cautious about declaring the IPO window truly open again given ongoing macroeconomic uncertainty.
15 Apr 2025 · 1 min read
I attended AbuDhabiGlobalHealthWeek and heard compelling talks on the UAE's AI and healthcare ambitions. The region is investing heavily in data infrastructure, international R&D partnerships, and the funding ecosystem needed to attract global investment.
13 Feb 2025 · 1 min read
I explore whether AI is truly rewriting the rules of drug discovery or just riding a wave of hype — from Latent Labs' €48M funding round to the real-world limits of fully in silico drug development. I genuinely believe we'll see the first 100% AI-discovered drug hit the market within the next 5–7 years.
29 Jan 2025 · 1 min read
Neko Health's $260M raise is a signal that prevention may finally be getting the prime-time moment it deserves. I reflect on why this investment matters for a part of healthcare that has long been underfunded despite being the most cost-effective way to manage disease.
28 Jan 2025 · 1 min read
It currently feels like a new techbio AI drug discovery play is launched on a weekly basis, showing the AI hype in this field isn't over yet. I'm curious to see how this new generation of companies will fare compared to previous biotech platform plays, given that many steps like MedChem and Toxicology still take time even with AI acceleration.
10 Dec 2024 · 1 min read
A lawsuit against VC firm Mohr Davidow Ventures over the collapse of billion-dollar healthcare startup HealthTap is a sobering case-study in the dark side of startup financing and the complex power dynamics between founders, employees, and investors. As an independent board member, I see these tensions regularly — and they'll only increase as 2021 valuations come back down to reality.
4 Dec 2024 · 1 min read
I attended a fascinating panel at Health Tech Forward on Automation in Clinical Trials featuring in-silico trials and digital twins. Speakers from QuantHealth, a leading VC, and United Therapeutics shared how AI is cutting trial lengths, replacing animal models, and opening new doors for orphan disease research.
10 Sept 2024 · 1 min read
Another significant $120M funding round has landed in AI-driven drug discovery, this time with Lilly leading alongside Nvidia and key VC funds. I'm optimistic that we could be witnessing the birth of the next Amgen, Genentech, or Biogen — powered by AI.
11 Jul 2024 · 1 min read
I flagged some encouraging digital health investment stats recently, but a key leading indicator — how much VCs are raising for their funds — is not looking great, across all domains. Without a trend breaker in IPO and M&A exit opportunities, it will become even harder for healthtech companies to raise money in the future.
27 Jun 2024 · 1 min read
Despite the challenging fundraising environment, we are witnessing significant investments in AI-enabled drug discovery and development. Formation Bio's nearly $400M Series D and Xaira Therapeutics' emergence from stealth mode signal intensifying competition among major VC funds to lead in AI-powered biotech innovations.